METHOD

In the COLATE trial, patients failing a 3TC-containing regimen (9/19 patients [3TC arm]) or discontinuing 3TC (No-3TC arm) whilst continuing or initiating a new three-drug regimen. All available cryopreserved plasma samples were used for protease and reverse transcriptase sequencing at baseline and during follow-up if HIV RNA >1000 c/ml. Patients were only included if baseline and ≥1 follow-up sequence was available.

Phylogenetic trees were created using the Neighbor-Joining distance method and the PAUP program was used to calculate the number of changed nucleotides since baseline (Jukes-Cantor distance).

RESULTS

We obtained a total of: 67 sequences in 19 patients (3TC arm) and 65 sequences in 23 patients (No-3TC arm).

Four sequences in patients in the No-3TC arm and one sequence in the 3TC arm were outliers in the phylogenetic trees. These patients were excluded from the analyses so that the evolutionary drift from baseline could be measured for the remaining patients without the interference of the outliers. The sequences for these patients have been marked in the phylogenetic trees shown in figure 2 and figure 3. After these exclusions we had 63 sequences for 18 patients (3TC) and 54 sequences for 12 patients (No-3TC) to include in our analysis.

The Jukes-Cantor distances show an increase in number of nucleotide changes from baseline to week 48, comparable between the two arms at all time points (Figure 1). At week 48 the median (IQR) nucleotide distances from baseline were: 2.05 (1.90, 2.14) and 4.05 (3.01, 11.12) in the 3TC arm vs. the No-3TC arm, respectively (p=0.49).

Similar results were found using the Kimura 2-parameter distance (n=13): 1.54 (0.46, 3.39) vs. 3.14 (0.78, 8.63; p=0.49) (Figure 4) and the Syn-Scan synonymous/non-synonymous method: 9.0 (5.0, 28.4) vs. 12.0 (8.5, 20.15; p=0.71) (Figure 5).

The observed increase in mutation rate for the No-3TC arm, at week 48 specifically, in the Jukes-Cantor and the Kimura 2-parameter methods cannot be confirmed when adjusting for the ambiguous nucleotide letters. The observed trend in a higher mutation rate in the No-3TC arm. Larger datasets and a longer follow-up time is needed to see if this is the case.

LIMITATIONS

Due to the small numbers of patients who could be included in these analyses there may not be sufficient power to identify any differences between evolutionary distances if they did exist.

This is a subgroup analysis of COLATE patients who failed to suppress viral replication therefore, even though these data are derived from a RCT, the randomised recruitment may not have ensured a comparable prior risk of viral evolution between treatment arms. However, the rate of suppression was comparable in the two arms in the parent trial implying a reduction in the possible bias.

CONCLUSION

In this study to the COLATE trial comparable mutation rates were found over 48 weeks among patients failing a 3TC-containing regimen who either continued or discontinued 3TC as part of HAART. Data at week 48 in two of the three analyses suggest there may be a trend in a higher mutation rate in the No-3TC arm. Larger datasets and a longer follow-up time is needed to see if this is the case.

REFERENCES

J Kjær, Z Fox, UB Dragsted, J Gerstoft, JD Lundgren and the COLATE study group
1 Copenhagen HIV Programme, Copenhagen, Denmark; 2 Rigshospitalet, Copenhagen, Denmark

BACKGROUND & OBJECTIVES

Virological failure on a regimen containing lamivudine (3TC) is associated with emergence of the M184V mutation. Previous studies suggest a higher fidelity of the mutant reverse transcriptase. Hypothetically, the presence of the M184V mutation would lead to a reduced rate over time in the evolution of other mutations in patients continuing 3TC compared to those discontinuing 3TC.

Two additional evolutionary nucleotide methods were applied:

- The Kimura 2-parameter distance that measures distances after accounting for the transversion/transition ratio.
- The Syn-Scan method that counts both synonymous (dS) and non-synonymous (dN) nucleotide changes and takes into account the information hidden by the ambiguous nucleotide letters.

The Kimura and Syn-Scan methods were used to test the differences between the 3TC arm and the No-3TC arm at all scheduled visits. Using the Bonferroni correction for multiple testing a p-value of 0.01 was considered to be significant.

Neighbour-joining distance tree for all sequence in the 3TC arm (Figure 2) and the no-3TC arm (Figure 3):

- Leaves marked with a shape have been excluded from the analysis.
- First number in the leave indicates the presence of the M184V mutation (1 = present, 0 = not present).
- The number between the two hyphens is the patient identifier.
- The last two-digit number is the week visit to which the sequence belongs.

Figure 2: 3TC arm

Figure 3: No-3TC arm

*Transition/Transversion

A transition is a mutational event between:
- Two purines (A → G or C → T).
- Two pyrimidines (C → T or G → A).

A transversion is a mutational event between:
- A purine and a pyrimidine (A → C or G → T).

Transitions happen more often than other transitions. The Kimura 2-parameter method takes the transversion/transversion ratio into account.

*Synonymous (dS)/Non-synonymous (dN)

- A synonymous mutation is a nucleotide change that does not result in change of an amino acid, a synonymous mutation is always in the third position of a codon.
- A non synonymous mutation is a nucleotide change that does result in change of an amino acid. The third or second position of a codon will always be a non-synonymous mutation.

The synonymous/non-synonymous ratio gives an indication of purine or pyrimidine selection. A ratio less than 1 indicates positive selection.

*Ambiguous nucleotide letters (UPAC codes)

- Letters that code for a mixture of A, C, T, G - E.g. K codes for purines (A and G) and M for pyrimidines (C and T).
- Common in HIV-1 sequence data - HIV-1 is a quasispecies and the letters reflect the diversity rather than the ambiguity.
- Letters are treated very differently in sequence programs - PAUP applies the shortest possible distance.
- Syn-Scan (http://www.ars.usda.gov/ARS/Location/RLA/papers/synscan.html) calculates the average distance.

C Philadelphia, PA 19104

PRINCIPAL INVESTIGATORS

Bergen: H. Cornelissen
Dresden: G. Wernich, T. Mathiesen, K. Pedersen
France: F. Deleure, G. Castaniere
Germany: T. D. Goebel, S. Staszewski
Greece: G. Peros
Ireland: P. Mulcahy
Italy: A. D. De Minico, M. Ronco
Norway: J. N. Bruus
Poland: A. Horban
Spain: F. De Leuw, B. Colom
Sweden: K. Gyllensten
United Kingdom: D. Churchill, M. Fletcher, B. Gazzard, M. Johnson, C. Leen


CHIP COPENHAGEN HIV PROGRAMME

7.9

The COLATE trial: Comparison of the Evolutionary Distance for Protease and Reverse Transcriptase Sequences